Lynparza godkänd i EU vid BRCA-muterad metastacerande pankreascancer
The approval by the European Commission was based on results from the Phase III POLO trial, which were published in The New England Journal of Medicine. It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Läs mer...
